Genomic and transcriptomic characterization of papillary microcarcinomas with lateral neck lymph node metastases.

CONTEXT Most papillary microcarcinomas (PMC) are indolent and subclinical, however as many as 10% can present with clinically significant nodal metastases. OBJECTIVE/DESIGN Characterization of the genomic and transcriptomic landscape of PMC presenting with or without clinically significant lymph node metastases. SUBJECTS/SAMPLES Formalin-fixed paraffin-embedded PMC samples from 40 patients with lateral neck nodal metastases (pN1b) and 71 PMC patients with documented absence of nodal disease (pN0). OUTCOME MEASURE(S) To interrogate DNA alterations in 410 genes commonly mutated in cancer and test for differential gene expression using a custom NanoString panel of 248 genes selected primarily based on their association with tumor size and nodal disease in the papillary thyroid cancer TCGA project. RESULTS The genomic landscapes of PMC with or without pN1b were similar. Mutations in TERT promoter (3%) and TP53 (1%) were exclusive to N1b cases. Transcriptomic analysis revealed differential expression of 43 genes in PMCs with pN1b compared to pN0. A random forest machine learning-based molecular classifier developed to predict regional lymph node metastasis demonstrated a negative predictive value of 0.98 and a positive predictive value of 0.72 at a prevalence of 10% pN1b disease. CONCLUSIONS The genomic landscape of tumors with pN1b and pN0 disease was similar, whereas 43 genes selected primarily by mining the TCGA RNAseq data were differentially expressed. This bioinformatics-driven approach to the development of a custom transcriptomic assay provides a basis for a molecular classifier for pN1b risk stratification in PMC.

[1]  V. Seshan,et al.  Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. , 2018, Cancer cell.

[2]  E. Sokol,et al.  Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers , 2018, Clinical Cancer Research.

[3]  T. Giordano Genomic Hallmarks of Thyroid Neoplasia. , 2018, Annual Review of Pathology.

[4]  A. Miyauchi,et al.  Low-risk papillary microcarcinoma of the thyroid: A review of active surveillance trials. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[5]  Oscar Lin,et al.  Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance , 2017, JAMA otolaryngology-- head & neck surgery.

[6]  V. Seshan,et al.  Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence , 2017, Clinical Cancer Research.

[7]  Liang Liu,et al.  SIRT6 is upregulated and associated with cancer aggressiveness in papillary thyroid cancer via BRAF/ERK/Mcl‑1 pathway. , 2017, International journal of oncology.

[8]  P. Soares,et al.  The Genetics of Papillary Microcarcinomas of the Thyroid: Diagnostic and Prognostic Implications , 2017, Current genomics.

[9]  Jin Hwa Kim,et al.  Clinicopathological Significance of Loss of p27Kip1 Expression in Papillary Thyroid Carcinoma , 2017, The International journal of biological markers.

[10]  Marija Milkovic Perisa,et al.  Expression of nm23-H1 and COX-2 in thyroid papillary carcinoma and microcarcinoma , 2017, Oncology letters.

[11]  D. Eterović,et al.  Cyclin D1, Ret and P27 Expression in Papillary Thyroid Microcarcinoma , 2017, Acta Clinica Croatica.

[12]  Yang Liu,et al.  Preoperative predictors of lateral neck lymph node metastasis in papillary thyroid microcarcinoma , 2017, Medicine.

[13]  J. van Griensven,et al.  Efficacy of Convalescent Plasma in Relation to Dose of Ebola Virus Antibodies. , 2016, The New England journal of medicine.

[14]  Jee Soo Kim,et al.  Routine Level 2b Dissection may be Recommended Only in N1b Papillary Thyroid Carcinoma with Three- or Four-Level Lateral Lymph Node Metastasis , 2016, Annals of Surgical Oncology.

[15]  J. Fagin,et al.  Biologic and Clinical Perspectives on Thyroid Cancer. , 2016, The New England journal of medicine.

[16]  Tae-Min Kim,et al.  Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular carcinoma , 2016, Oncotarget.

[17]  Sun Wook Cho,et al.  Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers , 2016, PLoS genetics.

[18]  J. Shah,et al.  An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer. , 2016, Thyroid : official journal of the American Thyroid Association.

[19]  C. Sander,et al.  Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. , 2016, The Journal of clinical investigation.

[20]  R. Sihota,et al.  Candidate genes involved in the susceptibility of primary open angle glaucoma. , 2016, Gene.

[21]  Su-Jin Shin,et al.  Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status , 2016, Annals of Surgical Oncology.

[22]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[23]  Jae Bok Lee,et al.  Endoplasmic reticulum aminopeptidase 2 is highly expressed in papillary thyroid microcarcinoma with cervical lymph node metastasis. , 2015, Journal of cancer research and therapeutics.

[24]  S. Mane,et al.  Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. , 2015, Human molecular genetics.

[25]  N. Lu,et al.  Expression of ki67 in papillary thyroid microcarcinoma and its clinical significance. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[26]  J. Fagin,et al.  Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Papillary Thyroid Carcinoma , 2014, Cell.

[28]  J. Bishop,et al.  BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Harrow,et al.  Systematic evaluation of spliced alignment programs for RNA-seq data , 2013, Nature Methods.

[30]  T. Chan,et al.  Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. , 2013, The Journal of clinical endocrinology and metabolism.

[31]  L. Larocca,et al.  BRAF (V600E) mutation analysis on liquid‐based cytology‐processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma , 2013, Cancer cytopathology.

[32]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[33]  P. Ladenson,et al.  Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. , 2013, JAMA.

[34]  N. Socci,et al.  Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. , 2013, The Journal of clinical endocrinology and metabolism.

[35]  H. Ryu,et al.  Histomorphological factors in the risk prediction of lymph node metastasis in papillary thyroid carcinoma , 2013, Histopathology.

[36]  D. Rubello,et al.  Aggressive Papillary Thyroid Microcarcinoma: Prognostic Factors and Therapeutic Strategy , 2013, Clinical nuclear medicine.

[37]  Joanna A Gibson,et al.  BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype–phenotype correlation , 2013, Modern Pathology.

[38]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[39]  Tao Huang,et al.  Multifocality and Total Tumor Diameter Predict Central Neck Lymph Node Metastases in Papillary Thyroid Microcarcinoma , 2013, Annals of Surgical Oncology.

[40]  Kyunghwa Han,et al.  Preoperative Prediction of Central Lymph Node Metastasis in Thyroid Papillary Microcarcinoma Using Clinicopathologic and Sonographic Features , 2013, World Journal of Surgery.

[41]  Xiangqian Zheng,et al.  Papillary Microcarcinoma of the Thyroid: Clinical Characteristics and BRAFV600E Mutational Status of 977 Cases , 2013, Annals of Surgical Oncology.

[42]  R. Ralhan,et al.  Immunohistochemical analysis based Ep-ICD subcellular localization index (ESLI) is a novel marker for metastatic papillary thyroid microcarcinoma , 2012, BMC Cancer.

[43]  J. Golmard,et al.  Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma. , 2012, European journal of endocrinology.

[44]  Y. Ko,et al.  Correlation of lymphatic vessel density and vascular endothelial growth factor with nodal metastasis in papillary thyroid microcarcinoma , 2012, Head & neck.

[45]  R. Seethala,et al.  A combined molecular‐pathologic score improves risk stratification of thyroid papillary microcarcinoma , 2012, Cancer.

[46]  Yon Seon Kim Patterns and Predictive Factors of Lateral Lymph Node Metastasis in Papillary Thyroid Microcarcinoma , 2012, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[47]  Yong-xue Zhu,et al.  Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. , 2012, The Journal of clinical endocrinology and metabolism.

[48]  E. Kebebew,et al.  Molecular pathways associated with mortality in papillary thyroid cancer. , 2011, Surgery.

[49]  Herb Chen,et al.  Should All Papillary Thyroid Microcarcinomas Be Aggressively Treated?: An Analysis of 18,445 Cases , 2011, Annals of surgery.

[50]  B. Niederle,et al.  Desmoplastic stromal reaction in papillary thyroid microcarcinoma , 2011, Histopathology.

[51]  O. Wang,et al.  The BRAF Mutation Is Predictive of Aggressive Clinicopathological Characteristics in Papillary Thyroid Microcarcinoma , 2010, Annals of Surgical Oncology.

[52]  D. Giordano,et al.  Treatment and prognostic factors of papillary thyroid microcarcinoma , 2010, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.

[53]  Eun-Kyung Kim,et al.  Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. , 2009, Radiology.

[54]  M. Gao,et al.  Analysis of Differential BRAFV600E Mutational Status in High Aggressive Papillary Thyroid Microcarcinoma , 2009, Annals of Surgical Oncology.

[55]  T. Sebo,et al.  Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. , 2008, Surgery.

[56]  L. Braverman,et al.  Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. , 2008, European journal of endocrinology.

[57]  J. Roh,et al.  Central Cervical Nodal Metastasis from Papillary Thyroid Microcarcinoma: Pattern and Factors Predictive of Nodal Metastasis , 2008, Annals of Surgical Oncology.

[58]  H. Min,et al.  S100A4 expression is associated with lymph node metastasis in papillary microcarcinoma of the thyroid , 2008, Modern Pathology.

[59]  M. Santoro,et al.  Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. , 2007, The Journal of clinical endocrinology and metabolism.

[60]  A. Russo,et al.  BRAFV600E mutation and p27kip1 expression in papillary carcinomas of the thyroid ≤1 cm and their paired lymph node metastases , 2007 .

[61]  Tae Yong Kim,et al.  The BRAF mutation is useful for prediction of clinical recurrence in low‐risk patients with conventional papillary thyroid carcinoma , 2006, Clinical endocrinology.

[62]  E. Pearce,et al.  Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. , 2006, The Journal of clinical endocrinology and metabolism.

[63]  P. Ladenson,et al.  BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. , 2005, The Journal of clinical endocrinology and metabolism.

[64]  A. Miyauchi,et al.  Papillary Microcarcinomas of the Thyroid with Preoperatively Detectable Lymph Node Metastasis Show Significantly Higher Aggressive Characteristics on Immunohistochemical Examination , 2005, Oncology.

[65]  A. Miyauchi,et al.  Ultrasonographically and Anatomopathologically Detectable Node Metastases in the Lateral Compartment as Indicators of Worse Relapse-free Survival in Patients with Papillary Thyroid Carcinoma , 2005, World Journal of Surgery.

[66]  J. Chan,et al.  Papillary microcarcinoma of the thyroid—Prognostic significance of lymph node metastasis and multifocality , 2003, Cancer.

[67]  Koichi Ito,et al.  Lymph Node Metastasis From 259 Papillary Thyroid Microcarcinomas: Frequency, Pattern of Occurrence and Recurrence, and Optimal Strategy for Neck Dissection , 2003, Annals of surgery.

[68]  A. Børglum,et al.  Assignment of the human tryptophanyl-tRNA synthetase gene (WARS) to chromosome 14q32.2 --> q32.32. , 1996, Cytogenetics and Cell Genetics.